156 related articles for article (PubMed ID: 37094749)
1. Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Diabetes Res Clin Pract; 2023 May; 199():110679. PubMed ID: 37094749
[TBL] [Abstract][Full Text] [Related]
2. Trends in prevalence of probable fibrotic non-alcoholic steatohepatitis in the United States, 1999-2016.
Ciardullo S; Perseghin G
Liver Int; 2023 Feb; 43(2):340-344. PubMed ID: 36565051
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis.
Tavaglione F; Jamialahmadi O; De Vincentis A; Qadri S; Mowlaei ME; Mancina RM; Ciociola E; Carotti S; Perrone G; Bruni V; Gallo IF; Tuccinardi D; Bianco C; Prati D; Manfrini S; Pozzilli P; Picardi A; Caricato M; Yki-Järvinen H; Valenti L; Vespasiani-Gentilucci U; Romeo S
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1523-1532.e1. PubMed ID: 35421583
[TBL] [Abstract][Full Text] [Related]
5. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients.
Canivet CM; Zheng MH; Qadri S; Vonghia L; Chuah KH; Costentin C; George J; Armandi A; Adams LA; Lange NF; Blanchet O; Moal V; Younes R; Roux M; Chan WK; Sturm N; Eslam M; Bugianesi E; Wang Z; Dufour JF; Francque S; Yki-Järvinen H; Zheng KI; Boursier J
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3097-3106.e10. PubMed ID: 37031715
[TBL] [Abstract][Full Text] [Related]
8. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
9. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018.
Vilar-Gomez E; Vuppalanchi R; Mladenovic A; Samala N; Gawrieh S; Newsome PN; Chalasani N
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):115-124.e7. PubMed ID: 34958922
[TBL] [Abstract][Full Text] [Related]
11. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
[TBL] [Abstract][Full Text] [Related]
12. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
Ravaioli F; Dajti E; Mantovani A; Newsome PN; Targher G; Colecchia A
Gut; 2023 Jul; 72(7):1399-1409. PubMed ID: 36599683
[TBL] [Abstract][Full Text] [Related]
15. Fibrosis nonalcoholic steatohepatitis index validation and applicability considering glycaemic severity and T2D duration.
Pina A; Meneses MJ; Ribeiro RT; Raposo JF; Macedo MP
Liver Int; 2022 Nov; 42(11):2577-2580. PubMed ID: 35993692
[TBL] [Abstract][Full Text] [Related]
16. Fibrotic NASH in Individuals with Obesity: a Cross-sectional Analysis of the Prevalence of this Significant Milestone of Disease Progression and Accuracy of a Non-invasive Marker for its Screening.
de Souza Echeverria L; Mounzer DLS; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E
Obes Surg; 2024 Feb; 34(2):389-395. PubMed ID: 38110785
[TBL] [Abstract][Full Text] [Related]
17. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE;
J Hepatol; 2024 Mar; ():. PubMed ID: 38548067
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
19. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
20. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]